Document:

Form of Medium-Term Notes, Series T

 Exhibit 4.3 

[Face of Note] 

Unless this certificate is presented by an authorized representative of The Depository Trust Company, a New York corporation
(“DTC”), to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of Cede & Co. or in such other name as requested by an authorized representative
of DTC (and any payment is made to Cede & Co. or such other entity as is requested by an authorized representative of DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the
registered owner hereof, Cede & Co., has an interest herein. 
  

	 CUSIP NO. 95001D2E9 
	 PRINCIPAL AMOUNT: $                

 REGISTERED NO.        

WELLS FARGO & COMPANY 

MEDIUM-TERM NOTE, SERIES T 

Due Nine Months or More From Date of Issue 

Notes due April 4, 2028 

WELLS FARGO & COMPANY, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter
called the “Company,” which term includes any successor corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to CEDE & Co., or registered assigns, the principal sum of
                                         
                                         
                                         
              ($                ) on April 4, 2028 (the “Stated Maturity
Date”) and to pay interest thereon from April 4, 2018 or from the most recent Interest Payment Date to which interest has been paid or duly provided for semi-annually on each April 4 and October 4, commencing October 4,
2018, and at Maturity (each, an “Interest Payment Date”), at the rate per annum specified below until the principal hereof is paid or made available for payment. The interest so payable, and punctually paid or duly provided for, on
any Interest Payment Date will, as provided in the Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Regular Record Date for such interest next
preceding such Interest Payment Date. The Regular Record Date for an Interest Payment Date shall be one Business Day prior to such Interest Payment Date. If an Interest Payment Date is not a Business Day, interest on this Security shall be payable
on the next day that is a Business Day, with the same force and effect as if made on such Interest Payment Date, and without any interest or other payment with respect to the delay. “Business Day” shall mean a day, other than a
Saturday or Sunday, that is neither a legal holiday nor a day on which banking institutions are authorized or required by law or regulation to close in New York, New York. 

Except as described below for the first Interest Period, on each Interest Payment Date, interest will be paid for the period
commencing on and including the immediately preceding Interest Payment Date and ending on and including the day immediately preceding that Interest 

 
Payment Date. This period is referred to as an “Interest Period.” The first Interest Period will commence on and include April 4, 2018 and end on and include October 3,
2018. Interest on this Security will be computed on the basis of a 360-day year of twelve 30-day months. 

The interest rate on this Security that will apply during an Interest Period will be as follows: 

 

			
	 Commencing April 4, 2018 and

ending April 3, 2022
	  	 3.50% per annum

	 Commencing April 4, 2022 and

ending April 3, 2028
	  	 4.50% per annum

 Any interest not punctually paid or duly provided for will forthwith cease to be payable to
the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted
Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the
requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in the Indenture. 

Payment of interest on this Security will be made in immediately available funds at the office or agency of the Company
maintained for that purpose in the City of Minneapolis, Minnesota in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts; provided, however, that, at the option of
the Company, payment of interest may be paid by check mailed to the Person entitled thereto at such Person’s last address as it appears in the Security Register or by wire transfer to such account as may have been designated by such Person.
Payment of principal of and interest on this Security at Maturity will be made against presentation of this Security at the office or agency of the Company maintained for that purpose in the City of Minneapolis, Minnesota. Notwithstanding the
foregoing, for so long as this Security is a Global Security registered in the name of the Depositary, payments of principal and interest on this Security will be made to the Depositary by wire transfer of immediately available funds. 

This Security is redeemable at the option of the Company, in whole but not in part, on any Optional Redemption Date at a
Redemption Price equal to 100% of the principal amount of this Security to be redeemed, plus any accrued but unpaid interest to, but excluding, the Redemption Date. The “Optional Redemption Dates” are quarterly on the 4th day of each January, April, July and October, commencing April 4, 2022 and ending January 4, 2028. Notice of any redemption will be mailed at least 5 but not more than 30 days before the
applicable Redemption Date to the Holder hereof. Unless the Company defaults in the payment of the Redemption Price, on or after the Redemption Date, interest will cease to accrue on this Security or the portion hereof called for redemption. 

This Security is not subject to repayment at the option of the Holder hereof prior to April 4, 2028. This Security is not
entitled to any sinking fund. 

  
 2 

 Reference is hereby made to the further provisions of this Security set
forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 

Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual
signature or its duly authorized agent under the Indenture referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

[The remainder of this page has been left intentionally blank] 

  
 3 

 IN WITNESS WHEREOF, the Company has caused this instrument to be
duly executed. 
 DATED: 
  

					
	WELLS FARGO & COMPANY
		
	By:	 	 
		 	
		 	Its:	 	

  

					
	Attest:	 	 
		 	
		 	Its:	 	

  

			
	 TRUSTEE’S CERTIFICATE OF

AUTHENTICATION
 This is one of the Securities of the

series designated therein described
 in the within-mentioned Indenture.

	
	 CITIBANK, N.A.,

      as Trustee

		
	By:	 	 
		 	Authorized Signature
	
	 OR

	
	 WELLS FARGO BANK, N.A.,

  as Authenticating Agent for the Trustee

		
	By:	 	 
		 	Authorized Signature

  
 4 

 [Reverse of Note] 

WELLS FARGO & COMPANY 

MEDIUM-TERM NOTE, SERIES T 

Due Nine Months or More From Date of Issue 

Notes due April 4, 2028 

This Security is one of a duly authorized issue of securities of the Company (herein called the
“Securities”), issued and to be issued in one or more series under an indenture dated as of February 21, 2017, as amended or supplemented from time to time (herein called the “Indenture”), between the Company
and Citibank, N.A., as Trustee (herein called the “Trustee,” which term includes any successor trustee under the Indenture), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the
respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities, and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is
one of the series of the Securities designated as Medium-Term Notes, Series T, of the Company. The Securities of this series will bear interest at a fixed rate or a floating rate. The Securities of this series may mature at different times, be
redeemable at different times or not at all, be repayable at the option of the Holder at different times or not at all and be denominated in different currencies. 

The Securities are issuable only in registered form without coupons and will be either
(a) book-entry securities represented by one or more Global Securities recorded in the book-entry system maintained by the Depositary or (b) certificated
securities issued to and registered in the names of, the beneficial owners or their nominees. 
 The Company agrees, to the
extent permitted by law, not to voluntarily claim the benefits of any laws concerning usurious rates of interest against a Holder of this Security. 

Modification and Waivers 

The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights
and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the
Securities at the time Outstanding of all series to be affected, acting together as a class. The Indenture also contains provisions permitting the Holders of a majority in principal amount of the Securities of all series at the time Outstanding
affected by certain provisions of the Indenture, acting together as a class, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with those provisions of the Indenture. Certain past defaults under the
Indenture and their consequences may be waived under the Indenture by the Holders of a majority in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series. Any such consent
or waiver by the Holder of this Security shall be conclusive and binding 

  
 5 

 
upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation
of such consent or waiver is made upon this Security. 
 Defeasance 

Section 403 and Article Fifteen of the Indenture and the provisions of clause (ii) of Section 401(1)(B) of the
Indenture, relating to defeasance at any time of (a) the entire indebtedness on this Security and (b) certain restrictive covenants, upon compliance by the Company with certain conditions set forth therein, shall not apply to this
Security. The remaining provisions of Section 401 of the Indenture shall apply to this Security. 
 Authorized Denominations 

This Security is issuable only in registered form without coupons in denominations of $1,000 or any amount in excess thereof
which is an integral multiple of $1,000. 
 Registration of Transfer 

Upon due presentment for registration of transfer of this Security at the office or agency of the Company in the City of
Minneapolis, Minnesota, a new Security or Securities of this series, with the same terms as this Security, in authorized denominations for an equal aggregate principal amount will be issued to the transferee in exchange herefor, as provided in the
Indenture and subject to the limitations provided therein and to the limitations described below, without charge except for any tax or other governmental charge imposed in connection therewith. 

This Security is exchangeable for definitive Securities in registered form only if (x) the Depositary notifies the
Company that it is unwilling or unable to continue as Depositary for this Security or if at any time the Depositary ceases to be a clearing agency registered under the Securities Exchange Act of 1934, as amended, and a successor depositary is not
appointed within 90 days after the Company receives such notice or becomes aware of such ineligibility, (y) the Company in its sole discretion determines that this Security shall be exchangeable for definitive Securities in registered form
and notifies the Trustee thereof or (z) an Event of Default with respect to the Securities represented hereby has occurred and is continuing. If this Security is exchangeable pursuant to the preceding sentence, it shall be exchangeable for
definitive Securities in registered form, bearing interest at the same rate, having the same date of issuance, Stated Maturity Date and other terms and of authorized denominations aggregating a like amount. 

This Security may not be transferred except as a whole by the Depositary to a nominee of the Depositary or by a nominee of the
Depositary to the Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a successor of the Depositary or a nominee of such successor. Except as provided above, owners of beneficial interests in this Global
Security will not be entitled to receive physical delivery of Securities in definitive form and will not be considered the Holders hereof for any purpose under the Indenture. 

Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company
or the Trustee may treat the Person in whose name this 

  
 6 

 
Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the
contrary. 
 Obligation of the Company Absolute 

No reference herein to the Indenture and no provision of this Security or the Indenture shall alter or impair the obligation
of the Company, which is absolute and unconditional, to pay the principal of and interest on this Security at the times, place and rate, and in the coin or currency, herein prescribed, except as otherwise provided in this Security. 

No Personal Recourse 

No recourse shall be had for the payment of the principal of or the interest on this Security, or for any claim based hereon,
or otherwise in respect hereof, or based on or in respect of the Indenture or any indenture supplemental thereto, against any incorporator, stockholder, officer or director, as such, past, present or future, of the Company or any successor
corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise, all such liability being, by the acceptance hereof and as part of the consideration for the issuance hereof,
expressly waived and released. 
 Defined Terms 

All terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the Indenture
unless otherwise defined in this Security. 
 Governing Law 

This Security shall be governed by and construed in accordance with the law of the State of New York, without regard to
principles of conflicts of laws. 

  
 7 

 ABBREVIATIONS 

The following abbreviations, when used in the inscription on the face of this instrument, shall be construed as though they
were written out in full according to applicable laws or regulations: 
  

					
	 TEN COM
	 	  -- 
	 	 as tenants in common

			
	 TEN ENT
	 	  -- 
	 	 as tenants by the entireties

			
	 JT TEN
	 	  -- 
	 	 as joint tenants with right

of survivorship and not
 as
tenants in common

  

									
	 UNIF GIFT MIN ACT
	 	  -- 
	 	 	 	 Custodian
	 	 
		 		 	(Cust)	 		 	(Minor)

  

	
	Under Uniform Gifts to Minors Act

	
	
	   

	(State)

 Additional abbreviations may also be used though not in the above list. 

FOR VALUE RECEIVED, the undersigned hereby sell(s) and transfer(s) unto 

 

	
	 Please Insert Social Security or
 Other
Identifying Number of Assignee

	
	   

  
  

 
  
  

 
 (PLEASE
PRINT OR TYPE NAME AND ADDRESS INCLUDING POSTAL ZIP CODE OF ASSIGNEE)

  
 8 

 the within Security of WELLS FARGO & COMPANY and does hereby irrevocably constitute
and appoint                                      attorney to
transfer the said Security on the books of the Company, with full power of substitution in the premises. 
 Dated:
                                         
        
  

	
	   

  

	
	   

 NOTICE: The signature to this assignment must correspond with the name as written upon the face of the
within instrument in every particular, without alteration or enlargement or any change whatever. 

  
 9Exhibit

This THIRD AMENDMENT TO THE THIRD SETTLEMENT AGREEMENT, dated October 3, 2017, between (i) Wright Medical Technology, Inc. (“Wright Medical”) and (ii) Plaintiffs’ Co-Lead Counsel appointed by the Hon. William S. Duffey in MDL No. 2329 (the “MDL”) and Plaintiffs’ Co-Lead Counsel appointed by the Hon. Jane Johnson in JCCP No. 4710 (the “JCCP”) (referred to collectively as “Plaintiffs’ Counsel”) (Plaintiffs’ Counsel and Wright Medical each a “Party” and collectively referred to as the “Parties”), is made pursuant to Section 13.10 of the Third Settlement Agreement dated October 3, 2017 (the “Third Settlement Agreement”).  The Third Settlement Agreement, as previously amended by the Second Amendment to the Third Settlement Agreement, shall be further amended as follows (the Third Settlement Agreement, as amended, and this Third Amendment being collectively referred to herein as the “Agreement”): 
		
	1.
	Section 3.1.2 of the Third Settlement Agreement, as amended by the Second Amendment, which originally read: 

All settlement payments under either the Standard Settlement Option or the EIF Option are contingent upon Wright Medical receiving at least Thirty-Five Million dollars ($35,000,000.00) of additional insurance payments from some or all of the following insurers: Federal Insurance Company, Lexington Insurance Company, Lloyd’s of London, or Catlin Specialty Insurance Company (“the Non-Settling Insurers”). The payments must be received between the date of execution of the Term Sheet (September 18, 2017) and March 30, 2018, and must be paid to reimburse Wright Medical for defense fees and costs, settlements and/or judgments paid or incurred in connection with a CONSERVE® Claim, DYNASTY® Claim, or LINEAGE® Claim, as those terms are defined above.  In the event that this contingency is not met, Wright Medical in its sole discretion may terminate this Agreement in its entirety, and the Parties and Eligible Claimants will return to their respective positions held prior to this Agreement, with all releases and dismissal stipulations that may have been provided deemed void, and either returned to Plaintiffs’ Counsel or destroyed.
Is hereby amended as follows:
All settlement payments under either the Standard Settlement Option or the EIF Option are contingent upon Wright Medical receiving at least Thirty-Five Million dollars ($35,000,000.00) of additional insurance payments from some or all of the following insurers: Federal Insurance Company, Lexington Insurance Company, Lloyd’s of London, or Catlin Specialty Insurance Company (“the Non-Settling Insurers”).  The payments must be received by Wright Medical between the date of execution of the Term Sheet (September 18, 2017) and March 30, 2018, and must be paid to reimburse Wright Medical for defense fees and costs, settlements and/or judgments paid or incurred in connection with a CONSERVE® Claim, DYNASTY® Claim, or LINEAGE® Claim, as those terms are defined above.  
If as of March 30, 2018, Wright Medical does not receive the full $35 million from the Non-Settling Insurers (any shortfall shall be referred to as the “Deficient Insurance Balance”), then by September 30, 2018, Wright Medical will, at its sole election, either: 
(1) make the full Deficient Insurance Balance available for payment to underlying claimants in which case Wright Medical will have met its full payment obligation under Section 10.4.3(a), as amended by this Third Amendment; or
(2) assign collectively to Eligible Claimants who opt-in to accept Individual Settlements of Eligible Claims, to prosecute at their own cost, Wright Medical's insurance claims that are 

assignable against any Non-Settling Insurers designated by Wright Medical to be responsible for the remaining Deficient Insurance Balance; and, in addition, Wright Medical and Plaintiffs’ Counsel will enter into a negotiated assignment agreement and good-faith stipulated judgment and covenant not to execute against Wright Medical (the “Stipulated Judgment and Covenant”), on more specific terms to be agreed to by the Parties, in the total amount of Five Hundred Forty One Million Dollars ($541,000,000.00).  The Stipulated Judgment and Covenant shall be collectible only against the insurance policies from 2008-2012 of any Non-Settling Insurer that Wright Medical designates on September 30, 2018, as responsible for the Deficient Insurance Balance.  The Stipulated Judgment and Covenant shall not be collectible from or against any assets of Wright Medical, or any of its parent, sister or affiliated entities, other than the designated insurance policies. 
In the event that Wright Medical's insurance claims are assigned to Eligible Claimants, as set forth above, and the Stipulated Judgment and Covenant is entered under this option 2, Wright Medical and Plaintiffs' Counsel further agree:
		
	(i)
	Wright Medical will fund contingently the amount of the remaining Deficient Insurance Balance, if any, beginning March 7, 2019, needed for any payment of Individual Settlements, provided that all requirements and prerequisites to payment of Individual Settlements under this Third Settlement Agreement have been satisfied.

		
	(ii.)
	Any action to enforce or collect on Wright Medical’s insurance claims and/or the Stipulated Judgment and Covenant will be brought in the names of the Eligible Claimants, as assignees of Wright Medical.

		
	(iii.)
	Plaintiffs’ Counsel shall have sole and exclusive authority to enforce or collect on Wright Medical’s assigned insurance claims and/or the Stipulated Judgment and Covenant.  No Eligible Claimant may bring any lawsuit, claim or other adversarial proceeding of any type to enforce or collect on Wright Medical’s assigned insurance claims and/or the Stipulated Judgment and Covenant.  By filing a Claim Election Form, each Eligible Claimant will be deemed expressly to have waived any and all right or ability to bring or pursue, except through Plaintiffs’ Counsel, any and all claims to enforce or collect on Wright Medical’s assigned insurance claims and/or the Stipulated Judgment and Covenant, including but not limited to any and all claims against Wright Medical, any insurance company or any entity establishing or holding a QSFA, Plaintiffs’ Counsel, or Eligible Claimant’s counsel to pay funds or take any other action required under this Third Settlement Agreement.  This does not restrict an Eligible Claimant’s rights to enforce his or her own Full and Final Confidential Individual Release and Settlement Agreement.  

		
	(iv.)
	The entire amount that Wright Medical funds of the Deficient Insurance Balance beginning March 7, 2019, plus interest at 10% calculated annually thereon, shall be reimbursed to Wright Medical, after deducting all attorney's fees and costs incurred by Eligible Claimants to prosecute claims against the Non-Settling Insurers, from any funds recovered by Eligible 

2

Claimants by way of settlement or otherwise from the Stipulated Judgment and Covenant and/or pursuit of the assigned insurance claims.
		
	(v.)  
	Wright Medical shall also recover up to an additional five million dollars ($5,000,000.00) if Wright Medical is required to fund any of the Deficient Insurance Balance beginning March 7, 2019, which shall be reimbursed to Wright Medical, after deducting all attorney's fees and costs incurred by Eligible Claimants to prosecute claims against the Non-Settling Insurers, from the first of any funds recovered by Eligible Claimants by way of settlement or otherwise from the Stipulated Judgment and Covenant and/or pursuit of the assigned insurance claims, in reimbursement of defense fees and costs, and other litigation expenses Wright Medical has incurred to date from claims by or against the Non-Settling Insurers.

		
	(vi)
	The Stipulated Judgment and Covenant and/or the assigned insurance claims will not be abandoned or dismissed, or settled with any Non-Settling Insurers in exchange for an aggregate amount less than $15,000,000.00, over and above the amounts set forth in Subsections (iv) and (v) above, unless Wright Medical is first given an option, in its sole discretion, to have the Stipulated Judgment and Covenant and/or the assigned insurance claims assigned back to Wright Medical, in exchange for payment by Wright Medical of the proposed settlement amount, if applicable.

		
	(vii.)  
	Except for recovery against Wright Medical’s insurance assets for which coverage is provided by the Non-Settling Insurers as set forth in this Third Amendment, under no circumstances will the total amount of Wright Medical’s obligations under this Third Settlement Agreement exceed $76,750,000.

		
	(viii.)
	No amounts collected pursuant to the Stipulated Judgment and Covenant will be distributed to any Eligible Claimant until such Eligible Claimant has complied with all requirements set forth in this Third Settlement Agreement, specifically including but not limited to, the requirements of Sections 4, 8.1, 7.1 and 9.1.2.

		
	2.
	Section 10.4.3 of the Third Settlement Agreement, which originally read:    

The following is the schedule under which funding will be available from Wright Medical for payment of Individual Settlements, provided that all requirements and prerequisites to payment under this Third Settlement Agreement have been satisfied:
(a)    $45,000,000.00 by June 30, 2018; and
(b)    $31,750,000.00 by September 30, 2019
Is hereby amended as follows:
The following is the schedule under which funding will be available from Wright Medical for payment of Individual Settlements, provided that all requirements and prerequisites to payment under this Third Settlement Agreement have been satisfied, and subject to Section 3.1.2:

3

(a)    $10,000,000.00 by June 30, 2018, plus any monies received by March 30, 2018, from Non-Settling Insurers up to $35,000,000.00, for a maximum combined total of $45,000,000.00; and
(b)    $31,750,000.00 by September 30, 2019

		
	3.
	Section 2.2 of the Third Settlement Agreement, which originally read:

The total amount of all Eligibility Adjustments will be confirmed and agreed to by the Parties; however, under no circumstance will the total amount of the settlement exceed $76,750,000.00.
Is hereby amended as follows:
The total amount of all Eligibility Adjustments will be confirmed and agreed to by the Parties; however, except for recovery against Wright Medical’s insurance assets for which coverage is provided by the Non-Settling Insurers as set forth in this Third Amendment, under no circumstance will the total amount of Wright Medical’s obligations under this Third Settlement Agreement exceed $76,750,000.00.

		
	4.
	Section 2.3 of the Third Settlement Agreement, which originally read:

This Third Settlement Agreement provides an opportunity for compensation pursuant to an extraordinary injury fund (“EIF”), as described below.  To be clear, regardless of any total or individual amounts allocated to EIF compensation, under no circumstances will the total settlement amount under this settlement exceed $76,750,000.00.  
Is hereby amended as follows:
This Third Settlement Agreement provides an opportunity for compensation pursuant to an extraordinary injury fund (“EIF”), as described below.  To be clear, regardless of any total or individual amounts allocated to EIF compensation, except for recovery against Wright Medical’s insurance assets for which coverage is provided by the Non-Settling Insurers as set forth in this Third Amendment, under no circumstances will the total amount of Wright Medical’s obligations under this Third Settlement Agreement exceed $76,750,000.00.  
The Agreement shall remain the same in all other respects.

4

IN WITNESS WHEREOF, the Parties have executed this Third Amendment to the Third Settlement Agreement as of October 3, 2017 on the dates indicated below. 

	
					
	PLAINTIFFS’ MDL AND JCCP CO-LEAD COUNSEL

	/s/ Michael L. McGlamry
	 
	/s/ Raymond P. Boucher

	Michael L. McGlamry
	 
	Raymond P. Boucher

	Pope, McGlamry, Kilpatrick, Morrison & Norwood, P.C.
	 
	Boucher LLP

	Dated:
	3/28/18
	 
	Dated:
	3/28/18

	WRIGHT MEDICAL TECHNOLOGY, INC.

	/s/ James Lightman
	 
	 
	 

	James Lightman
	 
	 
	 

	Sr. Vice President and General Counsel
Wright Medical Technology, Inc.
	 
	 
	 

	Dated:
	3/29/18
	 
	 
	 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]